Luigi M.E. Grimaldi

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy

Alison Halliday, Richard Bulbulia, Leo H. Bonati et al. · The Lancet · 2021 · 312 citations · Full text

Medicine, Neurosurgery, Surgery +17

Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1α

Roberto Dominici, Monica Cattaneo, Giulia Malferrari et al. · Immunogenetics · 2002 · 192 citations

Life Sciences, Genetics, Molecular Biology +15

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 185 citations

Life Sciences, Immunology, Neurology +11